English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Currently the most accepted definition of Recurrent Implantation Failure (RIF) ,is the absence of achieving clinical pregnancy following transfer of 3 or more good quality embryos in women under 35 years age as well as 4 or in ≥ 35 years age women in fresh or frozen ET’s We had reviewed earlier comprehensively how to manage the endometrial factor in cases of RIF utilizing antibiotics not only orally but further using intrauterine antibiotics and then Platelet Rich Plasma (PRP).Despite that there are certain cases that refuse to respond .We have further delved deeper into pathophysiology of Recurrent Implantation Failure (RIF) along with describing innovatively the use of Mesenchymal Stem Cells (MSCs) cells derived from endometrial stem cells in 29 cases of RIF mixed with PRP that was successful in 23/29 cases besides improving Endometrial Thickness (EMT), but further in Clinical Pregnancy (CP) as well as Live Birth Delivery Rates (LBDR). Further we describe the role of Platelet and Endothelial Cell Adhesion Molecule 1 (PECAM) along with Transforming Growth Factor Beta (TGFβ) besides CDYL in RIF.

Management of Resistant Endometrium in Cases of Recurrent Implantation Failure Using Endometrial Mesenchymal Stem Cells as an Innovative Regenerative Therapy-A Short Communication